Literature DB >> 17910072

The chromosome 9q subtelomere deletion syndrome.

Douglas R Stewart1, Tjitske Kleefstra.   

Abstract

The chromosome 9q subtelomere deletion syndrome (9qSTDS) is among the first and most common clinically recognizable syndromes to arise from widespread testing by fluorescent in situ hybridization (FISH) of subtelomere deletions. There are about 50 reported cases worldwide. Affected individuals invariably have severe hypotonia with speech and gross motor delay. The facial gestalt is distinct and features absolute or relative micro- or brachycephaly, hypertelorism, synophrys, and/or arched eyebrows, mid-face hypoplasia, a short nose with upturned nares, a protruding tongue with everted lower lip and down-turned corners of the mouth. Approximately half of affected individuals have congenital heart defects (primarily ASD or VSD). A significant minority have epilepsy and/or behavioral and sleep disturbances. A variety of other major and minor eye, ear, genital, and limb anomalies have been reported. Most patients have sub-microscopic deletions of the subtelomere region of chromosome 9q34.3 that range from <400 kb to >3 Mb. The 9qSTDS is caused by haplo-insufficiency of EHMT1, a gene whose protein product (Eu-HMTase1) is a histone H3 Lys 9 (H3-K9) methyltransferase. This was established by identification of three patients with features of the syndrome and either mutations or a balanced translocation in EHMT1. H3-K9 histone methylation is restricted to the euchromatin of mammals and functions to silence individual genes. Deletion size does not correlate with the severity of the 9qSTDS since patients with mutations in EHMT1 are as severely affected as those with submicroscopic deletions. Patients clinically suspected of having the 9qSTDS but with normal subtelomere deletion testing by FISH or MLPA should be considered for detailed 9q MLPA analysis and/or sequencing of EHMT1. EHMT1 is another example in the growing list of genes responsible for brain development that appear to play a role in chromatin remodeling. Published 2007 Wiley-Liss, Inc. (c) 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2007        PMID: 17910072     DOI: 10.1002/ajmg.c.30148

Source DB:  PubMed          Journal:  Am J Med Genet C Semin Med Genet        ISSN: 1552-4868            Impact factor:   3.908


  20 in total

1.  Disruption of an EHMT1-associated chromatin-modification module causes intellectual disability.

Authors:  Tjitske Kleefstra; Jamie M Kramer; Kornelia Neveling; Marjolein H Willemsen; Tom S Koemans; Lisenka E L M Vissers; Willemijn Wissink-Lindhout; Michaela Fenckova; Willem M R van den Akker; Nael Nadif Kasri; Willy M Nillesen; Trine Prescott; Robin D Clark; Koenraad Devriendt; Jeroen van Reeuwijk; Arjan P M de Brouwer; Christian Gilissen; Huiqing Zhou; Han G Brunner; Joris A Veltman; Annette Schenck; Hans van Bokhoven
Journal:  Am J Hum Genet       Date:  2012-06-21       Impact factor: 11.025

Review 2.  Genetic basis of congenital cardiovascular malformations.

Authors:  Seema R Lalani; John W Belmont
Journal:  Eur J Med Genet       Date:  2014-04-30       Impact factor: 2.708

Review 3.  Coordinated chromatin control: structural and functional linkage of DNA and histone methylation.

Authors:  Xiaodong Cheng; Robert M Blumenthal
Journal:  Biochemistry       Date:  2010-04-13       Impact factor: 3.162

Review 4.  Reversible histone methylation regulates brain gene expression and behavior.

Authors:  Jun Xu; Megan Andreassi
Journal:  Horm Behav       Date:  2010-09-15       Impact factor: 3.587

Review 5.  Herpesviruses and chromosomal integration.

Authors:  Guillaume Morissette; Louis Flamand
Journal:  J Virol       Date:  2010-09-15       Impact factor: 5.103

6.  Epileptogenesis: can the science of epigenetics give us answers?

Authors:  Farah D Lubin
Journal:  Epilepsy Curr       Date:  2012-05       Impact factor: 7.500

7.  Update on Kleefstra Syndrome.

Authors:  M H Willemsen; A T Vulto-van Silfhout; W M Nillesen; W M Wissink-Lindhout; H van Bokhoven; N Philip; E M Berry-Kravis; U Kini; C M A van Ravenswaaij-Arts; B Delle Chiaie; A M M Innes; G Houge; T Kosonen; K Cremer; M Fannemel; A Stray-Pedersen; W Reardon; J Ignatius; K Lachlan; C Mircher; P T J M Helderman van den Enden; M Mastebroek; P E Cohn-Hokke; H G Yntema; S Drunat; T Kleefstra
Journal:  Mol Syndromol       Date:  2012-01-24

8.  Trypanosoma brucei TIF2 suppresses VSG switching by maintaining subtelomere integrity.

Authors:  Sanaa E Jehi; Fan Wu; Bibo Li
Journal:  Cell Res       Date:  2014-05-09       Impact factor: 25.617

9.  Disruption of MBD5 contributes to a spectrum of psychopathology and neurodevelopmental abnormalities.

Authors:  J C Hodge; E Mitchell; V Pillalamarri; T L Toler; F Bartel; H M Kearney; Y S Zou; W H Tan; C Hanscom; S Kirmani; R R Hanson; S A Skinner; R C Rogers; D B Everman; E Boyd; C Tapp; S V Mullegama; D Keelean-Fuller; C M Powell; S H Elsea; C C Morton; J F Gusella; B DuPont; A Chaubey; A E Lin; M E Talkowski
Journal:  Mol Psychiatry       Date:  2013-04-16       Impact factor: 15.992

10.  A modified form of diphthamide causes immunotoxin resistance in a lymphoma cell line with a deletion of the WDR85 gene.

Authors:  Hui Wei; Tapan K Bera; Alan S Wayne; Laiman Xiang; Simona Colantonio; Oleg Chertov; Ira Pastan
Journal:  J Biol Chem       Date:  2013-03-13       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.